Abstract
The ability of clinicians to wage an effective war against many bacterial infections is increasingly being hampered by skyrocketing rates of antibiotic resistance. Indeed, antibiotic resistance is a significant problem for treatment of diseases caused by virtually all known infectious bacteria. The gastric pathogen Helicobacter pylori is no exception to this rule. With more than 50% of the world's population infected, H. pylori exacts a tremendous medical burden and represents an interesting paradigm for cancer development; it is the only bacterium that is currently recognized as a carcinogen. It is now firmly established that H. pylori infection is associated with diseases such as gastritis, peptic and duodenal ulceration and two forms of gastric cancer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. With such a large percentage of the population infected, increasing rates of antibiotic resistance are particularly vexing for a treatment regime that is already fairly complicated; treatment consists of two antibiotics and a proton pump inhibitor. To date, resistance has been found to all primary and secondary lines of antibiotic treatment as well as to drugs used for rescue therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 190-203 |
| Number of pages | 14 |
| Journal | Current Drug Therapy |
| Volume | 3 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2008 Sep 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology, Toxicology and Pharmaceutics(all)
- Pharmacology (medical)
Cite this
}
Who's winning the war? Molecular mechanisms of antibiotic resistance in Helicobacter pylori. / Jones, Kathleen R.; Cha, Jeong Heon; Merrell, D. Scott.
In: Current Drug Therapy, Vol. 3, No. 3, 01.09.2008, p. 190-203.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Who's winning the war? Molecular mechanisms of antibiotic resistance in Helicobacter pylori
AU - Jones, Kathleen R.
AU - Cha, Jeong Heon
AU - Merrell, D. Scott
PY - 2008/9/1
Y1 - 2008/9/1
N2 - The ability of clinicians to wage an effective war against many bacterial infections is increasingly being hampered by skyrocketing rates of antibiotic resistance. Indeed, antibiotic resistance is a significant problem for treatment of diseases caused by virtually all known infectious bacteria. The gastric pathogen Helicobacter pylori is no exception to this rule. With more than 50% of the world's population infected, H. pylori exacts a tremendous medical burden and represents an interesting paradigm for cancer development; it is the only bacterium that is currently recognized as a carcinogen. It is now firmly established that H. pylori infection is associated with diseases such as gastritis, peptic and duodenal ulceration and two forms of gastric cancer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. With such a large percentage of the population infected, increasing rates of antibiotic resistance are particularly vexing for a treatment regime that is already fairly complicated; treatment consists of two antibiotics and a proton pump inhibitor. To date, resistance has been found to all primary and secondary lines of antibiotic treatment as well as to drugs used for rescue therapy.
AB - The ability of clinicians to wage an effective war against many bacterial infections is increasingly being hampered by skyrocketing rates of antibiotic resistance. Indeed, antibiotic resistance is a significant problem for treatment of diseases caused by virtually all known infectious bacteria. The gastric pathogen Helicobacter pylori is no exception to this rule. With more than 50% of the world's population infected, H. pylori exacts a tremendous medical burden and represents an interesting paradigm for cancer development; it is the only bacterium that is currently recognized as a carcinogen. It is now firmly established that H. pylori infection is associated with diseases such as gastritis, peptic and duodenal ulceration and two forms of gastric cancer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. With such a large percentage of the population infected, increasing rates of antibiotic resistance are particularly vexing for a treatment regime that is already fairly complicated; treatment consists of two antibiotics and a proton pump inhibitor. To date, resistance has been found to all primary and secondary lines of antibiotic treatment as well as to drugs used for rescue therapy.
UR - http://www.scopus.com/inward/record.url?scp=54849407182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=54849407182&partnerID=8YFLogxK
U2 - 10.2174/157488508785747899
DO - 10.2174/157488508785747899
M3 - Review article
AN - SCOPUS:54849407182
VL - 3
SP - 190
EP - 203
JO - Current Drug Therapy
JF - Current Drug Therapy
SN - 1574-8855
IS - 3
ER -